Aridis Pharmaceuticals, Inc. focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb)to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin.
